Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
ZLCS [NASD]
Zalicus Inc.
Index- P/E- EPS (ttm)-1.42 Insider Own5.47% Shs Outstand2.61M Perf Week0.00%
Market Cap3.08M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-9.23%
Income- PEG- EPS next Q- Inst Own10.90% Short Float- Perf Quarter8.26%
Sales12.66M P/S0.24 EPS this Y- Inst Trans109.28% Short Ratio0.77 Perf Half Y-25.32%
Book/sh4.08 P/B0.29 EPS next Y- ROA- Target Price- Perf Year-59.86%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.86 - 8.28 Perf YTD6.31%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-85.75% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low37.21% ATR0.09
Employees27 Current Ratio- Sales Q/Q-56.40% Oper. Margin- RSI (14)51.00 Volatility5.62% 5.48%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.35 Prev Close1.18
ShortableYes LT Debt/Eq- EarningsJul 28 Payout- Avg Volume870.03K Price1.18
Recom- SMA20-3.04% SMA506.04% SMA200-35.24% Volume0 Change0.00%
07-Mar-13Reiterated MLV & Co Hold $0.50 → $0.75
10-Oct-12Downgrade MLV & Co Hold → Sell $0.50
11-Sep-12Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
10-Sep-12Downgrade MLV & Co Buy → Hold
21-Dec-11Initiated MLV & Co Buy $4
27-Sep-11Reiterated Oppenheimer Outperform $4 → $3
12-Sep-11Initiated Canaccord Genuity Buy $3
07-Jul-11Initiated Rodman & Renshaw Mkt Outperform $5
05-Jul-11Initiated Oppenheimer Outperform $4
25-Mar-11Initiated JMP Securities Mkt Outperform $5
15-Jul-14 05:19PM  EPIRUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Material Modi EDGAR Online
02-Jul-14 04:19PM  ZALICUS INC. Files SEC form 8-K, Termination of a Material Definitive Agreement EDGAR Online
25-Jun-14 08:38AM  ZALICUS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
08:38AM  ZALICUS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  Zalicus and Epirus Agree Zalicus Stockholders to Own 19% of Combined Company Post-Merger Business Wire
08:30AM  Zalicus and Epirus Agree Zalicus Stockholders to Own 19% of Combined Company Post-Merger
18-Jun-14 01:18PM  ZALICUS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and E EDGAR Online +8.00%
01:18PM  ZALICUS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and E
08:30AM  Zalicus Licenses Sodium Channel Pain Modulation Program Business Wire
08:30AM  Zalicus Licenses Sodium Channel Pain Modulation Program
12-Jun-14 11:10AM  Why Zalicus (ZLCS) Stock Is Surging Today at TheStreet +39.81%
11:10AM  Why Zalicus (ZLCS) Stock Is Surging Today
06-Jun-14 09:23AM  ZALICUS INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Results of Operations and Financ EDGAR Online
09:23AM  ZALICUS INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Results of Operations and Financ
02-Jun-14 09:33AM  Zalicus Announces Closing of cHTS Service Business Sale to Horizon Discovery Group Business Wire
09:33AM  Zalicus Announces Closing of cHTS Service Business Sale to Horizon Discovery Group
22-May-14 08:01AM  Zalicus updates progress on Z944 clinical development at theflyonthewall.com +8.60%
08:01AM  Zalicus updates progress on Z944 clinical development
08:00AM  Zalicus Updates Progress on Z944 Clinical Development Business Wire
08:00AM  Zalicus Updates Progress on Z944 Clinical Development
16-May-14 01:04PM  ZALICUS INC. Financials EDGAR Online Financials
01:04PM  ZALICUS INC. Financials
15-May-14 07:56AM  ZALICUS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and E EDGAR Online +6.52%
07:56AM  ZALICUS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and E
07:31AM  Zalicus to sell cHTS service business to Horizon Discovery Group for $8M at theflyonthewall.com
07:31AM  Zalicus to sell cHTS service business to Horizon Discovery Group for $8M
07:30AM  Zalicus to Sell cHTS Service Business to Horizon Discovery Group Business Wire
10-May-14 02:09PM  Zalicus To Be Acquired By Epirus Biopharma at Seeking Alpha
09-May-14 08:08AM  ZALICUS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online -6.25%
07:32AM  Zalicus sees Epirus deal closing in summer 2014 at theflyonthewall.com
07:32AM  Zalicus reports Q1 EPS (15c), may not compare to one estimate 20c at theflyonthewall.com
07:30AM  Zalicus Reports Financial Results for the First Quarter 2014 Business Wire
08-May-14 08:11AM  ZALICUS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online
28-Apr-14 04:38PM  Zalicus Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Merger with Epirus Biopharmaceuticals Business Wire
23-Apr-14 03:30PM  INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of Zalicus, Inc. and Its Board of Directors In Connection With the Sale of the Company to Epirus Biopharmaceuticals, Inc. Business Wire
16-Apr-14 04:50PM  SHAREHOLDER ALERT: Brower Piven Announces the Investigation of Zalicus, Inc. over the Proposed Merger with Epirus Biopharmaceuticals, Inc. Business Wire +31.07%
04:35PM  ZALICUS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and E EDGAR Online
12:51PM  SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Zalicus, Inc. - ZLCS PR Newswire
10:47AM  Why Zalicus (ZLCS) Stock Is Soaring Today at TheStreet
07:00AM  Zalicus and Epirus Announce Merger Agreement Business Wire
07:00AM  Epirus Closes $36 Million Series B Financing Business Wire
07:00AM  Epirus and Zalicus Announce Merger Agreement Business Wire
01-Apr-14 09:43AM  ZALICUS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
08:30AM  Zalicus to Present at AACR 2014 Annual Meeting Business Wire
19-Mar-14 01:04PM  ZALICUS INC. Financials EDGAR Online Financials
14-Mar-14 08:01AM  ZALICUS INC. Files SEC form 10-K, Annual Report EDGAR Online -5.30%
13-Mar-14 07:37AM  ZALICUS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:30AM  Zalicus Reports Financial Results for the Fourth Quarter and Year-End 2013 Business Wire
07:30AM  Zalicus Reports Financial Results for the Fourth Quarter and Year-End 2013
07-Feb-14 04:05PM  ZALICUS INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online +6.99%
05-Feb-14 11:46AM  Zalicus Improves Balance Sheet, Focuses On Z944 at Seeking Alpha
11:46AM  Zalicus Improves Balance Sheet, Focuses On Z944
03-Feb-14 08:30AM  ZALICUS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agr EDGAR Online -5.44%
09-Jan-14 11:13AM  Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better at TheStreet -11.24%
11:13AM  Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better
03-Jan-14 03:19PM  5 Stocks Poised for Breakouts at TheStreet +8.93%
03:19PM  5 Stocks Poised for Breakouts
15-Nov-13 12:02PM  Zalicus: Where From Here? at Seeking Alpha
12:02PM  Zalicus: Where From Here?
12-Nov-13 08:00AM  ZALICUS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online -13.85%
08:00AM  ZALICUS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
11-Nov-13 12:00PM  Zalicus skids after failure of its top drug AP -72.28%
12:00PM  Zalicus skids after failure of its top drug
11:30AM  Zalicus Plunges on Pain Drug Blowup at TheStreet
11:30AM  Zalicus Plunges on Pain Drug Blowup
11:05AM  Zalicus' Z160 Fails, What Now? at Seeking Alpha
11:05AM  Zalicus' Z160 Fails, What Now?
10:58AM  Zalicus: Investors Get Sucker Punched at Seeking Alpha
10:58AM  Zalicus: Investors Get Sucker Punched
09:56AM  Zalicus plunges after pain drug development discontinued at theflyonthewall.com
09:56AM  Zalicus plunges after pain drug development discontinued
08:44AM  Zalicus drops pain drug after trial failures Reuters
08:44AM  Zalicus drops pain drug after trial failures
08:30AM  InPlay: Zalicus reports Z160 did not meet the primary endpoint in either of the Phase 2 clinical studies; company to discontinue Z160 clinical development Briefing.com
08:30AM  Zalicus Reports Results from Phase 2 Clinical Trials of Z160 in Chronic Neuropathic Pain Business Wire
08-Nov-13 01:04PM  ZALICUS INC. Financials EDGAR Online Financials +11.93%
08:56AM  Key Issues Surrounding The Zalicus Catalyst Trade at Seeking Alpha
06-Nov-13 09:08AM  Clues And Controversy: Why Zalicus Shares Could Be Set For A Rally at Seeking Alpha
05-Nov-13 02:06PM  Where Is Zalicus After Trial Results? at Seeking Alpha
04-Nov-13 07:35AM  ZALICUS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online -7.73%
07:34AM  Zalicus says 'on track' to report two Z160 Phase 2 trials in Q4 at theflyonthewall.com
07:30AM  Zalicus Reports Financial Results for the Third Quarter 2013 Business Wire
01-Nov-13 08:37AM  ZALICUS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
08:35AM  Zalicus announces Z944 Phase 1b clinical study positive results theflyonthewall.com
08:32AM  InPlay: Zalicus announces positive results of Z944 Phase 1b clinical study in pain; efficacy signals in inflammatory and neuropathic pain observed; second U.S. patent issues for Z944 providing exclusivity to 2029 Briefing.com
08:30AM  Zalicus Announces Positive Results of Z944 Phase 1b Clinical Study in Pain Business Wire
29-Oct-13 05:27AM  Recent FDA News Makes A Zalicus Trade Look Even More Compelling at Seeking Alpha +5.02%
24-Oct-13 11:06AM  Zalicus: An Upcoming Catalyst With Huge Potential at Seeking Alpha +25.83%
15-Oct-13 09:45AM  Zalicus regains compliance on Nasdaq price rule AP
09:10AM  4 Biotechnology Stocks With Room To Climb at Seeking Alpha
07:47AM  Zalicus regains compliance with Nasdaq listing requirements theflyonthewall.com
07:35AM  ZALICUS INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tran EDGAR Online
07:33AM  InPlay: Zalicus regains compliance with nasdaq listing requirements Briefing.com
07:30AM  Zalicus Regains Compliance with Nasdaq Listing Requirements Business Wire
07-Oct-13 06:03PM  Nasdaq stocks posting largest percentage decreases AP
02:15PM  Nasdaq stocks posting largest percentage decreases AP
04-Oct-13 06:03PM  Nasdaq stocks posting largest percentage decreases AP -11.32%
01:20PM  Nasdaq stocks posting largest percentage decreases AP
03-Oct-13 06:04PM  Nasdaq stocks posting largest percentage decreases AP -11.67%
01:58PM  Nasdaq stocks posting largest percentage decreases AP
As of July 15, 2014, Zalicus Inc. was acquired by EPIRUS Biopharmaceuticals, Inc., in a reverse merger transaction. Zalicus Inc., a biopharmaceutical company, discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company has collaboration agreements with Mallinckrodt Inc.; Fovea Pharmaceuticals SA; Institutes of BioMedical Research, Inc.; Amgen Inc.; and United States Army Medical Research Institute. The company was formerly known as CombinatoRx, Incorporated and changed its name to Zalicus Inc. in September 2010. Zalicus Inc. was founded in 2000 and is based in Cambridge, Massachusetts.